Evaluation of a new optical imaging agent in dogs with naturally-occurring tumors

Purpose of study
Using an optical imaging agent to detect cancerous tumors. Fluorocoxib A is a non-steroidal anti-inflammatory drug (NSAID) with an attached fluorescent dye. Fluorocoxib A is taken up in tumors that have high levels of COX-2 enzymes. This enzyme is produced only in tumor cells, not normal cells. Using Fluorocoxib A can help determine the margins of tumors that would result in better determining the extent of the disease and more complete tumor removal.

Eligibility criteria
• Female dogs between 12 and 60 pounds.
• Must have a bladder mass detectable on ultrasound
• Other NSAIDs will have to be stopped 2 weeks before scoping
• Dogs must be otherwise healthy and suitable for anesthesia

Study details and costs
An appointment for evaluation at UTCVM will need to be made through the Oncology service or the Internal Medicine service. The scoping appointment will NOT be done the same day as the evaluation appointment. The patient may need to spend the night in ICU post scoping for monitoring.

A full estimate will be given to the client during the first visit. The referral visit fee is $132. The client will be responsible for costs associated with the full evaluation appointment, which will be approximately $1,100.

Study benefits
The study will pay for anesthesia during scoping, scoping fees, histology fees, primary cancer cell isolation in the lab, and a personalized treatment plan using primary cancer cells in vitro (value up to $1,200).

Think you have an eligible patient?
Contact Gina Galyon, LVMT - ggalyon@utk.edu | 865-974-8387

Primary Investigator: Dr. Maria Cekanova, UTCVM Oncology Service
Co-Investigators: Dr. Shelly Olin, Dr. Jacqui Whittemore, Dr. Katie Tolbert, Dr. Jennifer Stokes, and Dr. Olya Martin

This study is IACUC-approved (#1964-0916).